IO Biotech, Inc. — Director's Dealing 2021

Nov 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2021-11-09

Reporting Person: Novo Holdings A/S (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-09	COMMON STOCK	C	2952932	—	Acquired	2952932	Direct
2021-11-09	COMMON STOCK	P	325000	$14.00	Acquired	3277932	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-09	SERIES B CONVERTIBLE PREFERRED STOCK	$	C	217107	Disposed		COMMON STOCK (2006715)	Direct
2021-11-09	SERIES C CONVERTIBLE PREFERRED STOCK	$	C	75267	Disposed		COMMON STOCK (946217)	Direct

Footnotes

F1: The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.